Skip to main content

Table 1 Demographics for TCGA HNSCC patients analyzed in this study (progressors and nonprogressors)

From: IL-10 and integrin signaling pathways are associated with head and neck cancer progression

  Patients (n = 235)
Age (mean) 20–90 (62)
Gender (M/F) 173(74 %)/62(26 %)
Race (W/B/A/AI/NA)a 212(90 %)/12(4.5 %)/4(2 %)/2(1 %)/5(2.5 %)
Smoke (Y/N/NA) 181(77 %)/52(22 %)/2(1 %)
Alcohol (Y/N/NA) 169(71.5 %)/61(26 %)/5(2.5 %)
HPV p16 or ISH (+/−/NA) 19(8 %)/49(21 %)/167(71 %)
Site (OC/OPX/L)b 135(57 %)/41(18 %)/59(25 %)
T Stage (T1-T2/T3/T4/TX/NA) 80(34 %)/64(27 %)/87(37 %)/3(1.5 %)/1(0.5 %)
N Stage (N0/N+/NA) 107(45.5 %)/127(54 %)/1(0.5 %)
Tumor Stage (I-III/IV/NA) 96(41 %)/135(57 %)/4(2 %)
Margin Status (+/−/Close/NA) 17(7 %)/158(67 %)/22(10 %)/38(16 %)
Nodal Extracapsular Spread (GE/ME/NE/NA)c 13(6 %)/34(14 %)/114(49 %)/74(31 %)
Curated Therapy: Therapy (C/R/CR/CRTM/CRTMV/NA)d 5(2 %)/60(26 %)/95(40 %)/1(0.5 %)/1(0.5 %)/73(31 %)
Radiation data: Radiation Dose cGy (mean) 9–7380 (4720)
Follow-up data: Follow-up Days (median) 45–4241 (530.5)
Follow-up data: Mortality (Living/Deceased) 164(69.5 %)/71(30.5 %)
Follow-up data: Days to Death (median) 23–5152 (456)
Follow-up data: Days to New Tumor (median) 50–1859 (339)
Radiation Treatment (Y/N) 165(70 %)/70(30 %)
Progression (Y/N) 68(29 %)/167(71 %)
  1. a W white, B black, A asian, AI American Indian
  2. b OC oral cavity, OPX oropharynx, L larynx
  3. c GE gross extension, ME microscopic extension, NE no extranodal Extension
  4. d C chemotherapy only, R radiation only, CR chemotherapy & radiation, CRTM chemotherapy, radiation & targeted molecular therapy, CRTMV chemotherapy, radiation, targeted molecular therapy & vaccine
  5. Gray Shaded rows indicate significant differences between progressors and nonprogressors (P < 0.05)